1 November 2017
|
Styliani Germanou, Sophie Merrick, Simon Chowdhury
|
Urologic Oncology
Castrate resistant prostate cancer (CRPC) is defined by disease progression despite androgen-deprivation therapy lowering testosterone to castrate levels. It may present as a rise in serum levels of prostate specific antigen (PSA), progression of pre-existing disease, or the appearance of...